Adil Javed to Humans
This is a "connection" page, showing publications Adil Javed has written about Humans.
Connection Strength
0.235
-
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
Score: 0.031
-
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study. Mult Scler Relat Disord. 2023 Jun; 74:104718.
Score: 0.029
-
Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399.
Score: 0.021
-
Acute disseminated encephalomyelitis. Handb Clin Neurol. 2014; 123:705-17.
Score: 0.015
-
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3.
Score: 0.014
-
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
Score: 0.013
-
Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol. 2011 Feb; 26(2):244-7.
Score: 0.012
-
Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Curr Opin Ophthalmol. 2009 Nov; 20(6):476-81.
Score: 0.011
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.010
-
Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol Ther. 2006 Apr; 110(1):35-56.
Score: 0.009
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.007
-
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2023 01; 10(1).
Score: 0.007
-
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778.
Score: 0.007
-
COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147.
Score: 0.006
-
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189.
Score: 0.006
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.005
-
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2019 05; 25(6):811-818.
Score: 0.005
-
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018 03; 80:331-336.
Score: 0.005
-
Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018; 13(1):e0190425.
Score: 0.005
-
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. J Neurol Sci. 2018 Jan 15; 384:61-66.
Score: 0.005
-
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299.
Score: 0.005
-
Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11.
Score: 0.003
-
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008 Feb; 7(2):173-83.
Score: 0.003